204 related articles for article (PubMed ID: 16297390)
1. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis.
Fisher SD; Miller TL; Lipshultz SE
Atherosclerosis; 2006 Mar; 185(1):1-11. PubMed ID: 16297390
[TBL] [Abstract][Full Text] [Related]
2. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
3. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.
Shafer RW; Vuitton DA
Biomed Pharmacother; 1999 Mar; 53(2):73-86. PubMed ID: 10337461
[TBL] [Abstract][Full Text] [Related]
4. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor.
Calista D; Morri M; Stagno A; Boschini A
Am J Clin Dermatol; 2002; 3(1):59-62. PubMed ID: 11817969
[TBL] [Abstract][Full Text] [Related]
5. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
6. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
7. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
[TBL] [Abstract][Full Text] [Related]
8. Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy.
Haser GC; Sumpio B
J Vasc Surg; 2017 Mar; 65(3):849-859. PubMed ID: 26994951
[TBL] [Abstract][Full Text] [Related]
9. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
Chou R; Fu R; Huffman LH; Korthuis PT
Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
[TBL] [Abstract][Full Text] [Related]
10. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.
Ceccato MG; Bonolo PF; Souza Neto AI; Araújo FS; Freitas MI
Braz J Med Biol Res; 2011 Nov; 44(11):1177-83. PubMed ID: 22052375
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
Shehu-Xhilaga M; Tachedjian G; Crowe SM; Kedzierska K
Curr Med Chem; 2005; 12(15):1705-19. PubMed ID: 16029143
[TBL] [Abstract][Full Text] [Related]
15. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.
Vilchez RA; Finch CJ; Jorgensen JL; Butel JS
Medicine (Baltimore); 2003 Mar; 82(2):77-81. PubMed ID: 12640183
[TBL] [Abstract][Full Text] [Related]
16. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
17. Lipid metabolism in treated HIV Infection.
Dubé MP; Cadden JJ
Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
[TBL] [Abstract][Full Text] [Related]
18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
19. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
[TBL] [Abstract][Full Text] [Related]
20. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
